Remdesivir, Favipiravir, and Ribavirin show potential in vitro antiviral activity against poliovirus.
Complete poliovirus eradication requires managing chronic excreters and controlling potential outbreaks. RNA-dependent RNA Polymerase (RdRp) inhibitors represent promising candidates for this purpose. The antiviral activities of Remdesivir, Favipiravir, and Ribavirin against Sabin-like poliovirus types 1 (SL1) and 3 (SL3) were evaluated in HeLa cells individually and in combination. Antiviral effects were measured by cytopathic effect inhibition, MTT assay, and qRT-PCR. Drug-drug interactions were analyzed using Synergy Finder Plus. Molecular docking was performed to evaluate RdRp binding affinity. Remdesivir demonstrated the modest activity with low EC
Soheili et al. (Fri,) studied this question.